Related references
Note: Only part of the references are listed.Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
S. Haubner et al.
LEUKEMIA (2019)
The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia
Nicolas Duployez et al.
LEUKEMIA (2019)
Study on the Prognostic Value of Aberrant Antigen in Patients With Acute B Lymphocytic Leukemia
Jun Liu et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia
Nana Arai et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2019)
Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML
Peter Valent et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
A novel method for detecting the cellular stemness state in normal and leukemic human hematopoietic cells can predict disease outcome and drug sensitivity
Muhammad Yassin et al.
LEUKEMIA (2019)
Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis
Matthew A. Loberg et al.
LEUKEMIA (2019)
Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies
Matthew R. Collinson-Pautz et al.
LEUKEMIA (2019)
Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia
Nolwenn Lucas et al.
LEUKEMIA (2019)
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation
Cristina Toffalori et al.
NATURE MEDICINE (2019)
Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT
Maddalena Noviello et al.
NATURE COMMUNICATIONS (2019)
Clonal hematopoiesis and preleukemia-Genetics, biology, and clinical implications
Luise Hartmann et al.
GENES CHROMOSOMES & CANCER (2019)
Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group
Olga K. Weinberg et al.
MODERN PATHOLOGY (2019)
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
Naveen Pemmaraju et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
Sibylle Cocciardi et al.
NATURE COMMUNICATIONS (2019)
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia
Christine M. McMahon et al.
CANCER DISCOVERY (2019)
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
Susanne Hofmann et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Blastic Plasmacytoid Dendritic Cell Neoplasm: State of the Art and Prospects
Maria Rosaria Sapienza et al.
CANCERS (2019)
Blastic Plasmacytoid Dendritic Cell Neoplasm-Current Insights
Sangeetha Venugopal et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?
Brian Ball et al.
HAEMATOLOGICA (2019)
Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?
Katherine D. Cummins et al.
HAEMATOLOGICA (2019)
Updates on CAR T-cell therapy in B-cell malignancies
Elad Jacoby et al.
IMMUNOLOGICAL REVIEWS (2019)
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance
Katsuhiro Togami et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients
Friederike Christen et al.
BLOOD (2019)
Mechanisms of immune escape after allogeneic hematopoietic cell transplantation
Robert Zeiser et al.
BLOOD (2019)
CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping
Anne E. Bras et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2019)
CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia
Evgeniya Angelova et al.
HAEMATOLOGICA (2019)
Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment
Christina Rautenberg et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation
Mareike Frick et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia
Bowen Yan et al.
LEUKEMIA (2019)
Single cell analysis of clonal architecture in acute myeloid leukaemia
Nicola Potter et al.
LEUKEMIA (2019)
CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia
Wendelien Zeijlemaker et al.
LEUKEMIA (2019)
Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level
Jiahao Chen et al.
NATURE MEDICINE (2019)
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
Musa Yilmaz et al.
BLOOD CANCER JOURNAL (2019)
Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1
Daniel Ernst et al.
BLOOD CANCER JOURNAL (2019)
Pediatric preclinical testing consortium evaluation of the CD123 antibody drug conjugate, IMGN632, against xenograft models of pediatric acute lymphoblastic leukemia
Kathryn Evans et al.
CANCER RESEARCH (2019)
Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation
Max Jan et al.
BLOOD ADVANCES (2019)
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia
Raphael Itzykson et al.
BLOOD (2018)
Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients
Philipp A. Greif et al.
CLINICAL CANCER RESEARCH (2018)
The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors
Rajeswaran Mani et al.
HAEMATOLOGICA (2018)
Relapse of acute myeloid leukemia after allogeneic stem cell transplantation is associated with gain of WT1 alterations and high mutation load
Sebastian Vosberg et al.
HAEMATOLOGICA (2018)
First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases
Weili Sun et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia
Jessica C. Petrov et al.
LEUKEMIA (2018)
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
M. Jongen-Lavrencic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
A dual role for the N-terminal domain of the IL-3 receptor in cell signalling
Sophie E. Broughton et al.
NATURE COMMUNICATIONS (2018)
The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors
Rajeswaran Mani et al.
HAEMATOLOGICA (2018)
Relapse of acute myeloid leukemia after allogeneic stem cell transplantation is associated with gain of WT1 alterations and high mutation load
Sebastian Vosberg et al.
HAEMATOLOGICA (2018)
Survival outcomes of CD34+CD38−LSCs and their expression of CD123 in adult AML patients
Asmaa M. Zahran et al.
Oncotarget (2018)
Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells
Todd A. Braciak et al.
ONCOIMMUNOLOGY (2018)
Immune Escape of Relapsed AML Cells after Allogeneic Transplantation
M. J. Christopher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Universal monitoring of minimal residual disease in acute myeloid leukemia
Elaine Coustan-Smith et al.
JCI INSIGHT (2018)
A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells
Yelena Kovtun et al.
BLOOD ADVANCES (2018)
Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 X CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Sergio Rutella et al.
BLOOD (2018)
Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant
Meagan A. Jacoby et al.
JCI INSIGHT (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
Michael R. Grever et al.
BLOOD (2017)
Dynamics of clonal evolution in myelodysplastic syndromes
Hideki Makishima et al.
NATURE GENETICS (2017)
Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells
Stephan Kloss et al.
HUMAN GENE THERAPY (2017)
Genomics of Acute Myeloid Leukemia Diagnosis and Pathways
Lars Bullinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Acute Myeloid Leukemia, Version 3.2017
Margaret R. O'Donnell et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells
A. Ray et al.
LEUKEMIA (2017)
Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia
Silvia Arcangeli et al.
MOLECULAR THERAPY (2017)
Tracing the origins of relapse in acute myeloid leukaemia to stem cells
Liran I. Shlush et al.
NATURE (2017)
CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission
L. H. Xie et al.
BLOOD CANCER JOURNAL (2017)
Classification and risk assessment in AML integrating cytogenetics and molecular profiling
Matahi Moarii et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2017)
Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia
Lina Han et al.
CLINICAL CANCER RESEARCH (2017)
Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia
Sarah K. Tasian et al.
BLOOD (2017)
Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform
Muneera Al-Hussaini et al.
BLOOD (2016)
Hematopoietic stem cell transplantation for patients with AML in first complete remission
Jan J. Cornelissen et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
Marco Ruella et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+delineate FLT3/ITD-positive clones
Adhra Al-Mawali et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Assessment of Minimal Residual Disease in Standard-Risk AML
A. Ivey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia
Lynn Quek et al.
BLOOD ADVANCES (2016)
Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells
Elvira Pelosi et al.
BLOOD CELLS MOLECULES AND DISEASES (2015)
A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia
Daniela F. Angelini et al.
CLINICAL CANCER RESEARCH (2015)
The βc receptor family - Structural insights and their functional implications
Sophie E. Broughton et al.
CYTOKINE (2015)
Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice
Erwin M. Lee et al.
HAEMATOLOGICA (2015)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates
Gurunadh R. Chichili et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice
Erwin M. Lee et al.
HAEMATOLOGICA (2015)
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
R. Coleman Lindsley et al.
BLOOD (2015)
In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent
Fanny Angelot-Delettre et al.
HAEMATOLOGICA (2015)
A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia
Simon Z. He et al.
LEUKEMIA & LYMPHOMA (2015)
Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells
Eva Nievergall et al.
BLOOD (2014)
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients
Arthur E. Frankel et al.
BLOOD (2014)
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
Saar Gill et al.
BLOOD (2014)
SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia
Olga Frolova et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC
S. J. Busfield et al.
LEUKEMIA (2014)
Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo
I. Pizzitola et al.
LEUKEMIA (2014)
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
A. Ehninger et al.
BLOOD CANCER JOURNAL (2014)
Dual Mechanism of Interleukin-3 Receptor Blockade by an Anti-Cancer Antibody
Sophie E. Broughton et al.
CELL REPORTS (2014)
CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
Ugo Testa et al.
BIOMARKER RESEARCH (2014)
Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation
Damien Roos-Weil et al.
BLOOD (2013)
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia
Armen Mardiros et al.
BLOOD (2013)
Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor
Sarah Tettamanti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Signalling by the βc family of cytokines
Timothy R. Hercus et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2013)
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study
Livio Pagano et al.
HAEMATOLOGICA (2013)
Distinguishing hairy cell leukemia variant from hairy cell leukemia: Development and validation of diagnostic criteria
Haipeng Shao et al.
LEUKEMIA RESEARCH (2013)
CD123 Immunohistochemical Expression in Acute Myeloid Leukemia is Associated With Underlying FLT3-ITD and NPM1 Mutations
Marian Rollins-Raval et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2013)
Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia
Keumrock Hwang et al.
ANNALS OF HEMATOLOGY (2012)
The Origin and Evolution of Mutations in Acute Myeloid Leukemia
John S. Welch et al.
CELL (2012)
The GM-CSF receptor family: Mechanism of activation and implications for disease
Timothy R. Hercus et al.
GROWTH FACTORS (2012)
The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling
Sophie E. Broughton et al.
IMMUNOLOGICAL REVIEWS (2012)
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Li Ding et al.
NATURE (2012)
Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells
Shu-Ru Kuo et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2012)
Characteristic CD103 and CD123 Expression Pattern Defines Hairy Cell Leukemia Usefulness of CD123 and CD1O3 in the Diagnosis of Mature B-Cell Lymphoproliferative Disorders
Girish Venkataraman et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
Genome-wide Profiling in AML Patients Relapsing after Allogeneic Hematopoietic Cell Transplantation
Miguel Waterhouse et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
New markers for minimal residual disease detection in acute lymphoblastic leukemia
Elaine Coustan-Smith et al.
BLOOD (2011)
Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations
Roberta Riccioni et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Flow Cytometric Analysis of CD123 is Useful for Immunophenotyping Classical Hodgkin Lymphoma
Jonathan R. Fromm
CYTOMETRY PART B-CLINICAL CYTOMETRY (2011)
High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study
Francois Vergez et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Distinct Expression Patterns of CD123 and CD34 on Normal Bone Marrow B-Cell Precursors (Hematogones) and B Lymphoblastic Leukemia Blasts
Nagwa M. Hassanein et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor
Roberta Riccioni et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells
Liqing Jin et al.
CELL STEM CELL (2009)
Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia
Miroslav Djokic et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia
Arthur Frankel et al.
LEUKEMIA & LYMPHOMA (2008)
Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice
Leman Yalcintepe et al.
BLOOD (2006)
Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors
DE Hogge et al.
CLINICAL CANCER RESEARCH (2006)
Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression
U Testa et al.
BLOOD (2005)
Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey
KA Cohen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys
KA Cohen et al.
LEUKEMIA & LYMPHOMA (2004)
Elevated expression of IL-3Rα in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis
U Testa et al.
BLOOD (2002)
Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells
ML Guzman et al.
BLOOD (2001)
Identification of a leukemic counterpart of the plasmacytoid dendritic cells
L Chaperot et al.
BLOOD (2001)
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells
CT Jordan et al.
LEUKEMIA (2000)
Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias
AE Frankel et al.
LEUKEMIA (2000)
Share Paper
